Essex Bio-Technology Ltd (1061)
Hong Kong Stock Exchange · Hong Kong · prices in HKD · close of 22 Oct 2026
Key indicators
| Last close | HKD 2.035 |
|---|---|
| 52-week range | 1.980 – 4.640 |
| Return, 1 month / 3 months | −4.7% / −17.5% |
| Return, 1 year / 3 years | −53.2% / −16.2% |
| Trend | Below its 200-day average |
| RSI (14) | 41 |
| Volatility (1 year) | 39.4% |
| Worst drawdown (1 year) | -56.0% |
| Average daily value traded | 0.67M HKD |
| Dividend yield | 5.9% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Essex Bio-Technology Ltd is a biopharmaceutical company that develops and makes protein-based medicines for wound healing and eye care. Its products are built around recombinant growth factors and are sold under brands such as Beifuji, including gels and eye drops used by hospitals, clinics and patients, mainly in mainland China and other Asian markets. The company is based in Hong Kong and carries out research, manufacturing and sales through its own subsidiaries.
On this site Essex Bio-Technology Ltd appears as a stock on the Hong Kong Stock Exchange (Hong Kong), code 1061, with prices in Hong Kong dollars (HKD). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Essex Bio-Technology Ltd (1061) trades on the Hong Kong Stock Exchange in Hong Kong. It last closed at HKD 2.035 on 22 October 2026.
Its price-based Market X-Ray is 39 out of 100 (a weak price profile), ranking 1,785 of 2,611 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 53.2% and over the last three months it fell 17.5%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Hong Kong Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 20 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -31.7% | ||
| From 52-week high | -55.9% | ||
| Momentum | 22 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -17.5% | ||
| 6-month return | -35.3% | ||
| 12-month return, skipping the last month | -50.9% | ||
| Stability (higher is calmer) | 55 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 39.4% | ||
| Worst drawdown, 1 year (smaller is calmer) | -56.0% | ||
| Liquidity | 58 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.67M HKD | ||
| Zero-volume days | 0.0% | ||
| Income | 59 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 5.9% | ||
| Years with dividends | 5 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
Returns
| 1 week | −3.1% |
|---|---|
| 1 month | −4.7% |
| 3 months | −17.5% |
| 6 months | −35.3% |
| 1 year | −53.2% |
| 3 years | −16.2% |
| 5 years | −57.9% |
Signals
| 50-day / 200-day average | 2.175 / 2.981 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.076 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 18 Aug 2026 | HKD 0.0500 |
| 28 May 2026 | HKD 0.0700 |
| 8 Sep 2025 | HKD 0.0700 |
| 23 May 2025 | HKD 0.0600 |
| 9 Sep 2024 | HKD 0.0600 |
| 30 May 2024 | HKD 0.0450 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Hong Kong Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.